Highlight
Bempedoic acid was associated with a 42% relative reduction in first venous thromboembolism event compared with placebo in a post hoc analysis of the CLEAR Outcomes randomized clinical trial.
The signal was directionally consistent for both deep vein thrombosis and pulmonary embolism, with hazard ratios of 0.56 and 0.61, respectively.
